

<b>Committee Name:</b> Interoperability Committee		
<b>Document Date:</b> 24 February 2020	<b>Document Version No.</b> 1.1	<b>Page 1 of 4</b>

## COMMITTEE CHARTER

### 1. PURPOSE

The Interoperability Committee is responsible for substantive, tactical, and technical work needed to establish and advance an industry consensus for an interoperable system to meet 2023 DSCSA requirements.

### 2. GOALS/OBJECTIVES

The Interoperability Committee's primary objectives for 2020 are to:

1. Develop and present a consensus-based industry blueprint for the secure, electronic, interoperable unit-level tracing, verification and reporting, as required under DSCSA, (referred to throughout as "interoperability") to the PDG Board. This work will define the following attributes for authorized<sup>1</sup> stakeholders of US DSCSA and cover:
  - a. the business requirements and vision for 2023 interoperability
  - b. the technical means of, and identification of standards for, establishing / sustaining interoperability
  - c. the necessary governance to assure compliance to the business requirements
  - d. the obligatory business practices necessary to minimize potential operational exceptions

*Note: The Interoperability Committee will also identify, for Board consideration and action, outside technical advisors that may be needed to support its work.*
2. Develop and execute the FDA pilot on governance, with learnings to be shared with PDG Board and FDA.

### 3. DELIVERABLES

1. Present to the PDG Board a work plan for a consensus-based blueprint by milestones and deliverable dates that includes:
  - a. A vision and key principles for interoperability.
  - b. Definition of key terminology (e.g., model, architecture, system and process, interoperability, electronic methods, tracing, prompt).
  - c. Definition of business requirements for key use cases which clearly define the minimum requirements of authorized stakeholders for complying with the 2023 DSCSA statute and associated FDA guidance (final or draft).
  - d. Definition of the functional system and process attributes, including identification of any existing or needed standards, for establishing and sustaining interoperability among authorized stakeholders based on the defined business requirements.
  - e. Rules around the necessary governance for assuring that the industry consensus requirements and functionality are maintained in a sustainable fashion in order for authorized stakeholders to stay compliant with DCSCA.
  - f. A Committee meeting schedule.
  - g. Project plan and key interim milestones.
  - h. A final comprehensive "Blueprint" document capturing these deliverables.
2. Establish and execute the FDA-approved governance pilot on a schedule and cadence that meets both PDG and FDA's expectations.

<sup>1</sup> The term authorized is used in the context of DSCSA sec 581 (2).

<b>Committee Name:</b> Interoperability Committee		
<b>Document Date:</b> 24 February 2020	<b>Document Version No.</b> 1.1	<b>Page 2 of 4</b>

- a. Test the structure and organization of PDG, including any lessons learned and recommendations to PDG Board to help further refine governance model.
  - b. Leverage a use case for determining “authorized” status of a trading partner to define system and processes to support interoperability.
3. Quarterly updates to Board and General Membership.

#### 4. SCOPE DEFINITION

The Interoperability Committee should develop industry consensus for interoperability that meets the following expectations.

1. Interoperability that complies with applicable legal requirements (*e.g.*, DSCSA Phase II, FDA guidance on DSCSA, antitrust requirements, data integrity guidance, etc.).
2. Focuses on feasible methods of meeting the statutory requirements for 2023, though it should enable and may note additional business benefits that could be considered in the future.
3. Maximize efficiency and cost-effectiveness for all without regard to company size.
4. Maximize opt-ins (*i.e.*, encourage broad voluntary adoption of systems and processes that are based on the vision).
5. Not favor any particular stakeholder or constituency.
6. Focuses on U.S. (DSCSA) requirements, but should not hinder (*i.e.*, should account for) global harmonization.
7. Consideration to studies or outputs from other constituencies that offer a means of leveraging the work but not necessarily bound to the prior work of any such constituencies.

Interoperability should address the architecture of systems and processes for interoperability. Such architecture should:

1. Define an interoperable system(s) for electronic tracing of product at the package and homogenous case level which:
  - a. Provides means of TI and TS to be exchanged in a secure, interoperable, electronic manner.
  - b. Identifies method(s) to assure the integrity of the product identifier data for each package in the transaction contained within the TI.
  - c. Addresses common practices, leading to processes, which facilitate verification of a product’s identifier at the package level to the source data of the verification.
  - d. Facilitates gathering the information necessary to produce the TI for each transaction going back to the manufacturer, including when, where and by whom gathering is to occur, who may request to gather, and how gathering is accomplished to secure the information gathered for the purpose of confidentiality.
  - e. Facilitates trading partners ability to respond with TI & TS for a product upon a request by the Secretary (or other appropriate Federal or State official) in the event of a recall or for the purposes of investigating a suspect or illegitimate product.
  - f. Considers the needs of large and small business (fewer than 25 FTEs) among all sectors of the pharmaceutical distribution supply chain.
  - g. Supports scalability of systems and processes as more users come on board and new use cases are developed.
  - h. Clearly allows for identification of the source of truth or information pertaining to a product’s identifier.
2. Define where and by whom governance is necessary to sustain the operations and technical characteristics of an interoperable system among authorized stakeholders once said system is established.

- Define technical work groups necessary to fulfill the requirements and functionality necessary to establish an industry consensus interoperable system.

## 5. PROJECT MILESTONES

See project timeline.

Milestone	Description	Date
MS1	Scope, objective, and metrics of FDA pilot established	Jan '20
MS2	Approve Charter	Feb '20
MS3	Definition of key terminology	Feb '20
MS4	Pilot activity concluded and report available	May '20
MS5	Publish Business Requirements for Interoperable System for verification, tracing and reporting.	May '20
MS6	Publish functional attributes that define the means for establishing and sustaining interoperability among authorized stakeholders	May '20
MS7	Publish work plan for technical working group(s) needed for an industry consensus Interoperable system.	May '20
MS8	Stage Gate Review - Present Published material to PDG Board and FDA for review and comment	Jun '20
MS9	Publish output of technical working groups	Sep '20
MS10	Present completed proposal for Interoperable System to PDG Board for review and comment	Oct '20
MS11	PDG Board provides recommendation for Interoperable System for PDG Membership	Dec '20

## 6. ASSUMPTIONS, CONSTRAINTS, DEPENDENCIES, and DEFINITIONS

Assumptions	Constraints	Dependencies
<ul style="list-style-type: none"> <li>A single industry governance model</li> <li>Unlikely to achieve industry-wide alignment on a single technology to meet 2023 interoperability</li> <li>Routine work product review and feedback with Board &amp; FDA on both FDA pilot and blueprint development</li> <li>Disruptive new technologies will not be introduced midstream</li> <li>Work should focus on how to meet 2023 requirements and not business value adds</li> </ul>	<ul style="list-style-type: none"> <li>Lack of clarity on 2023 requirements could lead to multiple interpretations of DSCSA impacting interoperability</li> <li>Lack of Membership growth / participation across all sectors</li> <li>Funding</li> <li>Identifying SMEs</li> <li>Time and availability/competing demands</li> </ul>	<ul style="list-style-type: none"> <li>2023 timeline as specified in DSCSA</li> <li>Alternate methods of compliance</li> <li>Participation and collaborative approach from all sectors, including Technology providers</li> <li>FDA engagement</li> <li>Standards development/adoption</li> <li>Timely FDA input</li> <li>Member openness, willingness to think creativity, and willingness to compromise</li> </ul>

**Definitions:** The following terms have the meaning set forth in/as used in the Drug Supply Chain Security Act (DSCSA):

- Transaction Information (TI)
- Transaction Statement (TS)

<b>Committee Name:</b> Interoperability Committee		
<b>Document Date:</b> 24 February 2020	<b>Document Version No.</b> 1.1	<b>Page 4 of 4</b>

- Trading Partner
- Interoperability
- Tracing
- Verification
- Systems and Processes

## 7. RELATED DOCUMENTS

DSCSA (21 U.S.C. 360eee, et seq.)

DSCSA Guidances (<https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-law-and-policies>)

Other relevant regulation and guidance

## 8. AUTHORIZATION

Approved by:	Board	Date
Approved by:	Committee Chair	Date